FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and a risk factor for both cardiovascular and hepatic related morbidity and mortality. The increasing prevalence of this disease requires novel therapeutic approaches to prevent disease progression. Farn...
Gespeichert in:
| Veröffentlicht in: | Current atherosclerosis reports 2015-04, Vol.17 (4), p.500-500, Article 16 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 500 |
|---|---|
| container_issue | 4 |
| container_start_page | 500 |
| container_title | Current atherosclerosis reports |
| container_volume | 17 |
| creator | Carr, Rotonya M. Reid, Andrea E. |
| description | Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and a risk factor for both cardiovascular and hepatic related morbidity and mortality. The increasing prevalence of this disease requires novel therapeutic approaches to prevent disease progression. Farnesoid X receptors are bile acid receptors with roles in lipid, glucose, and energy homeostasis. Synthetic farnesoid X receptor (FXR) agonists have been developed to specifically target these receptors for therapeutic use in NAFLD patients. Here, we present a review of bile acid physiology and how agonism of FXR receptors has been examined in pre-clinical and clinical NAFLD. Early evidence suggests a potential role for synthetic FXR agonists in the management of NAFLD; however, additional studies are needed to clarify their effects on lipid and glucose parameters in humans. |
| doi_str_mv | 10.1007/s11883-015-0500-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1657324654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1657324654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-59f77b9d162ef9c1ccdb316df6d618c242a21908acb352af338533edc6849fb83</originalsourceid><addsrcrecordid>eNp9kDFPwzAQhS0EoqXwA1hQRhaDz44dZ6wKpUgVSKhIbJbjOG2qNC52gtR_j6sAI9Od7r17uvsQugZyB4Rk9wFASoYJcEw4IZieoDFwlmJBU3p67CnDTJJ0hC5C2BJCiRRwjkaUi5zwnIzRYv7xlkzXrq1DFxIdktXGer23fVebOLdtnFbOJy-uxboxbuOaKMx11x2SZf1lffJQB6uDvURnlW6CvfqpE_Q-f1zNFnj5-vQ8my6xSYF0mOdVlhV5CYLaKjdgTFkwEGUlSgHSxLs1hZxIbQrGqa4Yk5wxWxoh07wqJJug2yF3791nb0OndnUwtml0a10fFAieMZoKnkYrDFbjXQjeVmrv6532BwVEHQGqAaCKANURoKJx5-Ynvi92tvzb-CUWDXQwhCi1a-vV1vW-jS__k_oN_wx6Eg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1657324654</pqid></control><display><type>article</type><title>FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Carr, Rotonya M. ; Reid, Andrea E.</creator><creatorcontrib>Carr, Rotonya M. ; Reid, Andrea E.</creatorcontrib><description>Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and a risk factor for both cardiovascular and hepatic related morbidity and mortality. The increasing prevalence of this disease requires novel therapeutic approaches to prevent disease progression. Farnesoid X receptors are bile acid receptors with roles in lipid, glucose, and energy homeostasis. Synthetic farnesoid X receptor (FXR) agonists have been developed to specifically target these receptors for therapeutic use in NAFLD patients. Here, we present a review of bile acid physiology and how agonism of FXR receptors has been examined in pre-clinical and clinical NAFLD. Early evidence suggests a potential role for synthetic FXR agonists in the management of NAFLD; however, additional studies are needed to clarify their effects on lipid and glucose parameters in humans.</description><identifier>ISSN: 1523-3804</identifier><identifier>EISSN: 1534-6242</identifier><identifier>DOI: 10.1007/s11883-015-0500-2</identifier><identifier>PMID: 25690590</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Angiology ; Bile Acids and Salts - metabolism ; Cardiology ; Chenodeoxycholic Acid - analogs & derivatives ; Chenodeoxycholic Acid - therapeutic use ; Cholagogues and Choleretics - therapeutic use ; Fatty Liver, Alcoholic - drug therapy ; Humans ; Medicine ; Medicine & Public Health ; NF-kappa B - metabolism ; Non-alcoholic Fatty Liver Disease - drug therapy ; Non-alcoholic Fatty Liver Disease - metabolism ; Nonstatin Drugs (EM deGoma ; Phosphoenolpyruvate Carboxykinase (ATP) - metabolism ; PPAR alpha - metabolism ; Receptors, Cytoplasmic and Nuclear - agonists ; Receptors, Cytoplasmic and Nuclear - metabolism ; Section Editor ; Sterol Regulatory Element Binding Protein 1 - metabolism ; Topical Collection on Nonstatin Drugs ; Ursodeoxycholic Acid - therapeutic use</subject><ispartof>Current atherosclerosis reports, 2015-04, Vol.17 (4), p.500-500, Article 16</ispartof><rights>Springer Science+Business Media New York 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-59f77b9d162ef9c1ccdb316df6d618c242a21908acb352af338533edc6849fb83</citedby><cites>FETCH-LOGICAL-c410t-59f77b9d162ef9c1ccdb316df6d618c242a21908acb352af338533edc6849fb83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11883-015-0500-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11883-015-0500-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25690590$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carr, Rotonya M.</creatorcontrib><creatorcontrib>Reid, Andrea E.</creatorcontrib><title>FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease</title><title>Current atherosclerosis reports</title><addtitle>Curr Atheroscler Rep</addtitle><addtitle>Curr Atheroscler Rep</addtitle><description>Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and a risk factor for both cardiovascular and hepatic related morbidity and mortality. The increasing prevalence of this disease requires novel therapeutic approaches to prevent disease progression. Farnesoid X receptors are bile acid receptors with roles in lipid, glucose, and energy homeostasis. Synthetic farnesoid X receptor (FXR) agonists have been developed to specifically target these receptors for therapeutic use in NAFLD patients. Here, we present a review of bile acid physiology and how agonism of FXR receptors has been examined in pre-clinical and clinical NAFLD. Early evidence suggests a potential role for synthetic FXR agonists in the management of NAFLD; however, additional studies are needed to clarify their effects on lipid and glucose parameters in humans.</description><subject>Angiology</subject><subject>Bile Acids and Salts - metabolism</subject><subject>Cardiology</subject><subject>Chenodeoxycholic Acid - analogs & derivatives</subject><subject>Chenodeoxycholic Acid - therapeutic use</subject><subject>Cholagogues and Choleretics - therapeutic use</subject><subject>Fatty Liver, Alcoholic - drug therapy</subject><subject>Humans</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>NF-kappa B - metabolism</subject><subject>Non-alcoholic Fatty Liver Disease - drug therapy</subject><subject>Non-alcoholic Fatty Liver Disease - metabolism</subject><subject>Nonstatin Drugs (EM deGoma</subject><subject>Phosphoenolpyruvate Carboxykinase (ATP) - metabolism</subject><subject>PPAR alpha - metabolism</subject><subject>Receptors, Cytoplasmic and Nuclear - agonists</subject><subject>Receptors, Cytoplasmic and Nuclear - metabolism</subject><subject>Section Editor</subject><subject>Sterol Regulatory Element Binding Protein 1 - metabolism</subject><subject>Topical Collection on Nonstatin Drugs</subject><subject>Ursodeoxycholic Acid - therapeutic use</subject><issn>1523-3804</issn><issn>1534-6242</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDFPwzAQhS0EoqXwA1hQRhaDz44dZ6wKpUgVSKhIbJbjOG2qNC52gtR_j6sAI9Od7r17uvsQugZyB4Rk9wFASoYJcEw4IZieoDFwlmJBU3p67CnDTJJ0hC5C2BJCiRRwjkaUi5zwnIzRYv7xlkzXrq1DFxIdktXGer23fVebOLdtnFbOJy-uxboxbuOaKMx11x2SZf1lffJQB6uDvURnlW6CvfqpE_Q-f1zNFnj5-vQ8my6xSYF0mOdVlhV5CYLaKjdgTFkwEGUlSgHSxLs1hZxIbQrGqa4Yk5wxWxoh07wqJJug2yF3791nb0OndnUwtml0a10fFAieMZoKnkYrDFbjXQjeVmrv6532BwVEHQGqAaCKANURoKJx5-Ynvi92tvzb-CUWDXQwhCi1a-vV1vW-jS__k_oN_wx6Eg</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Carr, Rotonya M.</creator><creator>Reid, Andrea E.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease</title><author>Carr, Rotonya M. ; Reid, Andrea E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-59f77b9d162ef9c1ccdb316df6d618c242a21908acb352af338533edc6849fb83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Angiology</topic><topic>Bile Acids and Salts - metabolism</topic><topic>Cardiology</topic><topic>Chenodeoxycholic Acid - analogs & derivatives</topic><topic>Chenodeoxycholic Acid - therapeutic use</topic><topic>Cholagogues and Choleretics - therapeutic use</topic><topic>Fatty Liver, Alcoholic - drug therapy</topic><topic>Humans</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>NF-kappa B - metabolism</topic><topic>Non-alcoholic Fatty Liver Disease - drug therapy</topic><topic>Non-alcoholic Fatty Liver Disease - metabolism</topic><topic>Nonstatin Drugs (EM deGoma</topic><topic>Phosphoenolpyruvate Carboxykinase (ATP) - metabolism</topic><topic>PPAR alpha - metabolism</topic><topic>Receptors, Cytoplasmic and Nuclear - agonists</topic><topic>Receptors, Cytoplasmic and Nuclear - metabolism</topic><topic>Section Editor</topic><topic>Sterol Regulatory Element Binding Protein 1 - metabolism</topic><topic>Topical Collection on Nonstatin Drugs</topic><topic>Ursodeoxycholic Acid - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carr, Rotonya M.</creatorcontrib><creatorcontrib>Reid, Andrea E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Current atherosclerosis reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carr, Rotonya M.</au><au>Reid, Andrea E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease</atitle><jtitle>Current atherosclerosis reports</jtitle><stitle>Curr Atheroscler Rep</stitle><addtitle>Curr Atheroscler Rep</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>17</volume><issue>4</issue><spage>500</spage><epage>500</epage><pages>500-500</pages><artnum>16</artnum><issn>1523-3804</issn><eissn>1534-6242</eissn><abstract>Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and a risk factor for both cardiovascular and hepatic related morbidity and mortality. The increasing prevalence of this disease requires novel therapeutic approaches to prevent disease progression. Farnesoid X receptors are bile acid receptors with roles in lipid, glucose, and energy homeostasis. Synthetic farnesoid X receptor (FXR) agonists have been developed to specifically target these receptors for therapeutic use in NAFLD patients. Here, we present a review of bile acid physiology and how agonism of FXR receptors has been examined in pre-clinical and clinical NAFLD. Early evidence suggests a potential role for synthetic FXR agonists in the management of NAFLD; however, additional studies are needed to clarify their effects on lipid and glucose parameters in humans.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>25690590</pmid><doi>10.1007/s11883-015-0500-2</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1523-3804 |
| ispartof | Current atherosclerosis reports, 2015-04, Vol.17 (4), p.500-500, Article 16 |
| issn | 1523-3804 1534-6242 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1657324654 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Angiology Bile Acids and Salts - metabolism Cardiology Chenodeoxycholic Acid - analogs & derivatives Chenodeoxycholic Acid - therapeutic use Cholagogues and Choleretics - therapeutic use Fatty Liver, Alcoholic - drug therapy Humans Medicine Medicine & Public Health NF-kappa B - metabolism Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - metabolism Nonstatin Drugs (EM deGoma Phosphoenolpyruvate Carboxykinase (ATP) - metabolism PPAR alpha - metabolism Receptors, Cytoplasmic and Nuclear - agonists Receptors, Cytoplasmic and Nuclear - metabolism Section Editor Sterol Regulatory Element Binding Protein 1 - metabolism Topical Collection on Nonstatin Drugs Ursodeoxycholic Acid - therapeutic use |
| title | FXR Agonists as Therapeutic Agents for Non-alcoholic Fatty Liver Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T17%3A35%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FXR%20Agonists%20as%20Therapeutic%20Agents%20for%20Non-alcoholic%20Fatty%20Liver%20Disease&rft.jtitle=Current%20atherosclerosis%20reports&rft.au=Carr,%20Rotonya%20M.&rft.date=2015-04-01&rft.volume=17&rft.issue=4&rft.spage=500&rft.epage=500&rft.pages=500-500&rft.artnum=16&rft.issn=1523-3804&rft.eissn=1534-6242&rft_id=info:doi/10.1007/s11883-015-0500-2&rft_dat=%3Cproquest_cross%3E1657324654%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1657324654&rft_id=info:pmid/25690590&rfr_iscdi=true |